SAT0208 How good elderly rheumatoid arthritis patients respond at first year of treatment with certolizumab pegol

Background: In rheumatoid arthritis (RA), the efficacy and safety of Certolizumab pegol (CZP) is well stablished, as reported in randomized clinical trials (RCT) 1 and some registries 2 . Only the 30% of RA patients are within the age range of 65 years or older. However, they are usually excluded from the RCT. Aging is associated with declining immune cell function and age-related comorbidities 3,4 . Objectives: The aim of this study was to determine the effectiveness and safety of CZP in elderly patients in a real world setting at 12 months follow-up. Methods: Observational longitudinal prospective study of RA patients from 40 sites in Spain. Variables (baseline, 3- and 12-month assessment): socio-demographics, smoking status, previous synthetic DMARD (sDMARD) and biological DMARD (bDMARD) use; TJC, SJC, ESR, CRP, DAS28. Response variables EULAR Moderate/Good Response and DAS28 remission and Safety were assessed. Low Disease Activity as DAS28 remission or mild DAS28. Descriptive, comparative and Logistic regression analyses were performed comparing 65 yr population. Kaplan-Meier survival curve was performed. Results: A total of 501 RA patients were included, 23% were aged ≥65 yr (mean age 70.8 (±4.5 SD)yr). Sociodemographics and baseline features are shown in table 1. Efficacy variables are shown in table 2. Conclusions: The effectiveness of CZP among ≥65 yr only differed from their younger counterparts from DAS28 remission rate, with a lower percentage, and side-effects (higher percentage, with higher comorbidities percentage too). However, after one year of real-life data CZP seemed as both safety and effective enough as younger RA patients in real-life scenario. References [1]Keystone E, et al. Ann Rheum Dis2014Dec;73(12):2094–100. [2]Torrente-Segarra V, et al. Mod Rheumatol2015Nov 7:1–6. [3]van Onna M, et al. BMC Musculoskelet Disord2016;17:184. [4]Cross M, et al. Ann Rheum Dis2014;73:1316–22.1. Disclosure of Interest: None declared